A third of small-to-mid-cap biotech firms are becoming profitable, with cash reserves projected to soar from $15B in 2025 to over $130B by 2030. This financial strength, combined with large-cap patent expirations, positions them not just as acquisition targets but as potential players in the M&A landscape themselves.

Argenx is using its blockbuster drug revenue to acquire Forte Biosciences. The goal is not just growth, but to apply its successful 'pipeline in a product' strategy—expanding one drug across many indications—to a newly acquired asset, demonstrating a repeatable playbook for scaling.

The old assumption that small biotechs struggle with commercialization ("short the launch") is fading. Acquirers now target companies like Verona and Intracellular that have already built successful sales operations. This de-risks the acquisition by proving the drug's market viability before the deal, signaling a maturation of the biotech sector.

The biotech sector lacks mid-cap companies because successful small firms are typically acquired by large pharma before reaching that stage. This creates a barbell structure of many small R&D shops and a few commercial giants. The assets, not the companies, transition from small to large.

The M&A landscape is evolving as a new tier of large, but not Big Pharma-sized, biotechs are now executing their own billion-dollar acquisitions. Companies like Neurocrine, BioMarin, and Genmab are creating a new class of strategic buyers, diversifying exit opportunities for smaller biotech firms.

As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.

Instead of solely relying on replicating internal R&D success, a proven biotech can create value by acquiring passive assets. This involves buying royalty streams on promising external products, leveraging the company's evaluation and deal-making expertise in a new way.

The M&A landscape is evolving beyond Big Pharma's patent cliff-driven acquisitions. Mid-to-large biotechs like BioMarin, Insight, and Ionis are now positioned as buyers, creating a richer, more diverse deal-making ecosystem.

While celebrated, the current wave of high-value acquisitions of promising companies like Sonora and Halda has a downside. It removes potential standalone success stories from the market, potentially weakening the public biotech index and depriving investors of future mid-cap growth engines.